NasdaqGS:ROIVBiotechs
Roivant Sciences Advances PH Programs As Investors Weigh Pipeline Milestones
Pulmovant, a Roivant company, has completed patient enrollment ahead of schedule in the Phase 2 PHocus trial of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Roivant Sciences (NasdaqGS:ROIV) has reported new positive Phase 2 data for brepocitinib in cutaneous sarcoidosis.
Both updates reflect ongoing clinical activity in areas of high unmet medical need across Roivant’s pipeline.
Roivant Sciences, traded as NasdaqGS:ROIV, focuses on developing and...